MTOR and tuberous sclerosis: mTOR inhibitors, administered as monotherapy or in combination, have been proposed as disease-modifying agents for TSC-related epilepsy and ISs, although their long-term use is limited by adverse effects and by the observation that the antiepileptic response may wane over time [144,145,146].